HALB - Halberd Corporation

Other OTC - Other OTC Delayed Price. Currency in USD

0.0082

-0.0004

(-4.65%)

At close: 03:59PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	0.0086
Open	0.0090
Bid	N/A x N/A
Ask	N/A x N/A
Day's Range	0.0075 - 0.0090
52 Week Range	0.0032 - 0.0196
Volume	1,696,524
Avg. Volume	1,603,263

Market Cap	1.739M
Beta (5Y Monthly)	-4.86
PE Ratio (TTM)	N/A
EPS (TTM)	-0.0000
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for HALB

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

ACCESSWIRE
Halberd CEO Mid-Quarter Update
Halberd Corporation (OTC PINK:HALB) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring the public up to date on a few of the most significant efforts.
ACCESSWIRE
Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete
Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has completed the initial phase of its preclinical model to establish baseline testing parameters and study endpoints for Halberd's groundbreaking patent-pending nasal spray.
ACCESSWIRE
Halberd Pre-Clinical Test Protocol Approved
Halberd Corporation (OTC PINK:HALB) researchers at Mississippi State University College of Veterinary Medicine have received approval of its test protocol, and test subjects have been ordered.
ACCESSWIRE
Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma
Halberd Corporation (OTC PINK:HALB) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma.
ACCESSWIRE
Halberd Corporation 1Q23 CEO Letter
Halberd Corporation(OTC PINK:HALB).
ACCESSWIRE
HALB CEO, CTO and YSU's Dr. Sturrus Discuss CDC, Research Discoveries etc., on "The Street Reports Podcasts" Listen Now!
Halberd Corporation's (OTC PINK:HALB) President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S. Felder, and Youngstown State University (YSU) Professor/lead researcher, Dr. Wm.
ACCESSWIRE
Halberd and YSU Interviewed on CBS Affiliate WKBN 5pm News as Research Advances
Halberd Corporation's (OTC PINK:HALB) successful patent protected research being conducted at Youngstown State University (YSU) on antibiotic resistant bacteria and deadly Candida auris was recently featured in a news segment on Youngstown, OH CBS News affiliate television station, WKBN. Professors and student scholar lab assistants are conducting this intricate research on samples provided by the CDC (Centers for Disease Control and Prevention).
ACCESSWIRE
Halberd Begins Preclinical Testing at Mississippi State University (MSU)
Halberd Corporation (OTC PINK:HALB) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI).
ACCESSWIRE
Halberd's Successful Meeting with CDC Leads to Expanded Testing of Antibiotic Resistant Pathogens
Halberd Corporation (OTC PINK:HALB) on March 29th met with five representatives from the Centers for Disease Control and Prevention (CDC). The CDC discussed Halberd's incredible success eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and deadly Candida auris samples previously provided by the CDC.
ACCESSWIRE
Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma
Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU. The testing will focus on Halberd's patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining head trauma.
ACCESSWIRE
Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University
Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC.
ACCESSWIRE
Halberd & Centers for Disease Control to Meet Regarding Eradication of Antibiotic Resistant Pathogens
Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd's incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and Candida auris samples previously provided by the CDC.
ACCESSWIRE
Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria
Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under 10 minutes.
ACCESSWIRE
Halberd Corporation Announces Breakthrough in Candida auris Treatment
/ Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing.
ACCESSWIRE
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria at Youngstown State University (YSU). The research is being carried out by Dr. Chester Cooper and Dr. W.
ACCESSWIRE
Halberd to Conduct Animal Tests of Nasal Spray that Blocks Negative Effects of Head Trauma
Halberd Corporation (OTC PINK:HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury.
ACCESSWIRE
Halberd Agrees to Animal Testing at Mississippi State University
Halberd Corporation's (OTC PINK:HALB) has agreed to conduct animal testing at Mississippi State University's (MSU) animal testing laboratory.
ACCESSWIRE
Halberd Corporation 2022 Year End CEO Letter and 2023 Goals
Halberd Corporation(OTC PINK:HALB) The second half of 2022 was a very busy time.
ACCESSWIRE
Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication
Halberd Corporation (OTC PINK:HALB) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication technology which successfully eradicated numerous Gram-Negative bacteria whose results were reported in an October 18, 2022 press release.
ACCESSWIRE
"The Street Podcast" Features Halberd's "Groundbreaking" Cancer Treatment Approach. Listen Now!
Halberd Corporation's (OTC-PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S.
ACCESSWIRE
CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
Halberd Corporation's (OTC-PINK:HALB) Covid research has led to a scientific article titled, "A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant." The article has been peer reviewed and accepted for publication, but has not yet been published.
ACCESSWIRE
Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
Halberd Corporation's (OTC PINK:HALB) Covid research has led to a scientific article titled, "A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant." The article has been peer reviewed and accepted for publication, but has not yet been published.
ACCESSWIRE
Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast Cancer
Halberd Corporation (OTC PINK:HALB) researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in their latest series of tests.
ACCESSWIRE
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
Halberd Corporation (OTC-PINK:HALB) has signed a contract with the Hamden Group. The Hamden Group is a newly formed corporation which consists of members of the Croden family and Darren Hamans, who have extensive experience in the sales and marketing of pharmaceutical products. Darren Hamans is a Consultant for Business Development of the Halberd Corporation.
ACCESSWIRE
Hartman, CEO, and Dr. Felder, CTO of Halberd Corp Featured on The Street Reports Podcast
Halberd Corporation (OTC PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S.